Access cutting-edge validation study of molecular diagnostic system treatment through this clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Ann Arbor location
Preparing your pre-screening questions…
Access validation study of molecular diagnostic system specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related validation study of molecular diagnostic system treatment provided free
Check if you qualify for this validation study of molecular diagnostic system clinical trial in Ann Arbor, MI
No-Cost Study Care
Local to Ann Arbor
Convenient for MI residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The current standard for biopsy-based diagnoses of dysfunction of kidney transplants is the Banff Classification which represents arbitrary international consensus. Recent data-driven approaches using molecular and conventional technologies indicate that mere consensus produces frequently incorrect diagnoses with potential harm to patients due to inappropriate treatment. To address this unmet need and improve diagnostics in the area of organ transplantation, the Alberta Transplant Applied Genomics Centre (ATAGC) has developed a new diagnostic system that combines the molecular and histopathological features of transplant biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. The present study will validate and refine this system in 500 prospectively unselected biopsies for clinical indications from American, Canadian and European centres in addition to 300 biopsies already collected. Due to a considerable interest and support from participating Centers, the study is further extended to 1500 prospective biopsies. Thus this is the extension of the INTERCOM study (INTERCOMEX). In addition to demonstrating the feasibility and value of this System in routine patient care and clinical trials, the study will develop and optimize a transparent and user-friendly reporting format to communicate this information to clinicians and obtain detailed feedback on how this system can best improve patient care.
Sponsor: University of Alberta
Yes, this clinical trial (NCT01299168) has an active research site in Ann Arbor, MI that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for validation study of molecular diagnostic system treatment options in Ann Arbor, MI, this clinical trial (NCT01299168) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Ann Arbor research site is actively enrolling participants for this clinical trial. You'll receive care from experienced validation study of molecular diagnostic system specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all validation study of molecular diagnostic system clinical trials near you to find additional studies recruiting in your area.
See all interstitial cystitis clinical trials recruiting in Ann Arbor — not just this study.
Browse Interstitial Cystitis Trials in Ann Arbor →